| Bioactivity | Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus. | ||||||
| Invitro | Liraglutide binds to the same receptors as does the endogenous metabolic hormone GLP-1. Liraglutide is an injectable drug for the treatment of type 2 diabetes, also can be used to treat obesity in adults with some related comorbidity. Liraglutide activated AMPK/SREBP1 pathway in oxLDL-stimulated Raw264.7 cells[1]. | ||||||
| Name | Liraglutide | ||||||
| CAS | 204656-20-2 | ||||||
| Shortening | HAEGTFTSDVSSYL-{N6-[N-(1-oxohexadecyl)-L-γ-Etamyl]-Glu}-GQAAKEFIAWLVRGRG | ||||||
| Formula | C172H265N43O51 | ||||||
| Molar Mass | 3751.26 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture and light
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
Liraglutide
CAS: 204656-20-2 F: C172H265N43O51 W: 3751.26
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.